Compare TMCI & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMCI | RPID |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.6M | 204.3M |
| IPO Year | 2021 | 2021 |
| Metric | TMCI | RPID |
|---|---|---|
| Price | $2.43 | $4.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $4.21 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 707.1K | 320.7K |
| Earning Date | 02-26-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $218,879,000.00 | $30,523,000.00 |
| Revenue This Year | $3.30 | $19.36 |
| Revenue Next Year | N/A | $21.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 7.90 | ★ 16.63 |
| 52 Week Low | $2.36 | $1.10 |
| 52 Week High | $10.79 | $4.88 |
| Indicator | TMCI | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 35.73 | 67.06 |
| Support Level | $2.56 | $4.01 |
| Resistance Level | $2.75 | $4.88 |
| Average True Range (ATR) | 0.17 | 0.40 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 5.88 | 89.29 |
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.